CN103180739B - 利用骨髓细胞生物标记诊断癌症 - Google Patents

利用骨髓细胞生物标记诊断癌症 Download PDF

Info

Publication number
CN103180739B
CN103180739B CN201180045200.3A CN201180045200A CN103180739B CN 103180739 B CN103180739 B CN 103180739B CN 201180045200 A CN201180045200 A CN 201180045200A CN 103180739 B CN103180739 B CN 103180739B
Authority
CN
China
Prior art keywords
cancer
patients
mdsc
treatment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180045200.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103180739A (zh
Inventor
哈普利特·辛格
斯特芬·沃尔特
蕾吉娜·门德日克
文森佐·勃朗特
苏珊娜·曼德鲁扎托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Publication of CN103180739A publication Critical patent/CN103180739A/zh
Application granted granted Critical
Publication of CN103180739B publication Critical patent/CN103180739B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
CN201180045200.3A 2010-09-21 2011-09-21 利用骨髓细胞生物标记诊断癌症 Expired - Fee Related CN103180739B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38478410P 2010-09-21 2010-09-21
GBGB1015765.9A GB201015765D0 (en) 2010-09-21 2010-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
US61/384,784 2010-09-21
GB1015765.9 2010-09-21
PCT/EP2011/066397 WO2012038463A2 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer

Publications (2)

Publication Number Publication Date
CN103180739A CN103180739A (zh) 2013-06-26
CN103180739B true CN103180739B (zh) 2016-08-03

Family

ID=43065538

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180045200.3A Expired - Fee Related CN103180739B (zh) 2010-09-21 2011-09-21 利用骨髓细胞生物标记诊断癌症

Country Status (10)

Country Link
US (1) US9671404B2 (https=)
EP (1) EP2619585B1 (https=)
JP (1) JP5970459B2 (https=)
KR (1) KR20130137635A (https=)
CN (1) CN103180739B (https=)
CA (1) CA2811070A1 (https=)
EA (1) EA201390413A1 (https=)
GB (1) GB201015765D0 (https=)
SG (2) SG188543A1 (https=)
WO (1) WO2012038463A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP3682896A1 (en) * 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
WO2013169913A1 (en) 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
WO2014159923A1 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Enhancement of vaccines
CN103743907B (zh) * 2013-07-24 2015-04-15 北京大学人民医院 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法
WO2015048748A1 (en) * 2013-09-30 2015-04-02 Board Of Regents, The University Of Texas System Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use
CN103626846B (zh) * 2013-11-08 2016-06-01 上海交通大学 与MDSCs特异性结合的配体多肽及药物输送系统
EP3012271A1 (en) * 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CA2990852A1 (en) * 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
AU2016318136B2 (en) 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
RS66062B1 (sr) 2016-04-14 2024-11-29 Ose Immunotherapeutics Nova anti-sirpa antitela i njihove terapijske primene
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN107102127B (zh) * 2017-04-07 2019-08-06 东北师范大学 一种人体外周血中单核样髓源抑制细胞的检测方法
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
WO2018221820A1 (ko) * 2017-06-02 2018-12-06 이종균 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
JP7395471B2 (ja) 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
KR102216725B1 (ko) * 2017-12-29 2021-02-17 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법
AU2019233577A1 (en) 2018-03-13 2020-09-03 Ose Immunotherapeutics Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
AU2019266231B2 (en) 2018-05-07 2025-08-21 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
CN110501483B (zh) * 2019-07-25 2020-12-29 同济大学 一种中草药活性的检测方法
TR202003833A1 (tr) 2020-03-12 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇
BR112023025194A2 (pt) 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用
CN117030580B (zh) * 2023-09-15 2024-07-16 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） LDNs在坏死性小肠结肠炎诊断中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US20040136973A1 (en) * 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion;Arnold H.Zea;《Cancer Res.》;20050415;第65卷(第8期);摘要，第3045页图1，右栏第1段 *
Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor-Based Antitumor Vaccine;P. Filipazzi;《Journal of Clinical Oncology》;20070620;第25卷(第18期);第2548页左栏，图1 *
MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis;DELANO MATTHEW J;《THE JOURNAL OF EXPERIMENTAL MEDICINE》;20070611;第20卷(第6期);第1466页左栏第1段 *
Myeloid-derived suppressor cells:more mechanisms for inhibiting antitumor immunity;Suzanne Ostrand-Rosenberg;《Cancer Immunol Immunother》;20100423;第59卷(第10期);第1593-1600页 *

Also Published As

Publication number Publication date
US9671404B2 (en) 2017-06-06
EP2619585A2 (en) 2013-07-31
WO2012038463A2 (en) 2012-03-29
GB201015765D0 (en) 2010-10-27
JP5970459B2 (ja) 2016-08-17
WO2012038463A3 (en) 2012-07-26
EP2619585B1 (en) 2017-03-01
SG10201510470WA (en) 2016-01-28
US20120070461A1 (en) 2012-03-22
JP2013539857A (ja) 2013-10-28
EA201390413A1 (ru) 2013-07-30
CN103180739A (zh) 2013-06-26
KR20130137635A (ko) 2013-12-17
SG188543A1 (en) 2013-04-30
CA2811070A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
CN103180739B (zh) 利用骨髓细胞生物标记诊断癌症
CN103384827B (zh) 用于预测癌症免疫治疗效果的生物标记
Haratani et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
Wu et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
Ohm et al. VEGF as a mediator of tumor-associated immunodeficiency
JPWO2010110346A1 (ja) 白血病幹細胞マーカー
TW201927809A (zh) 個人化癌症疫苗的製備方法
US20210017607A1 (en) Methods of Predicting Responsiveness to Cancer Therapies
Kazama et al. Distribution of regulatory T-cells and other phenotypes of T-cells in tumors and regional lymph nodes of colorectal cancer patients
Martín-Sierra et al. Functional and phenotypic characterization of tumor-infiltrating leukocyte subsets and their contribution to the pathogenesis of hepatocellular carcinoma and cholangiocarcinoma
Yu et al. CCR9-CCL25 mediated plasmacytoid dendritic cell homing and contributed the immunosuppressive microenvironment in gastric cancer
JP7216420B2 (ja) がん治療効果の検査方法及び免疫応答誘導用組成物
JP2024151758A (ja) 肝臓癌を治療する方法、治療に対する応答を予測する方法、及び肝臓癌の治療中の有害作用を予測する方法
Xu et al. Downregulation of Hlx closely related to the decreased expressions of T-bet and Runx3 in patients with gastric cancer may be associated with a pathological event leading to the imbalance of Th1/Th2
Zahran et al. The frequency and clinical implications of lymphocyte subsets and circulating plasma cells in newly diagnosed multiple myeloma patients
WO2023218399A1 (en) Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies
Pourmir Membrane and soluble forms of the immune checkpoint TIM-3 in clear cell renal cell carcinoma: a promising biomarker for cancer immunotherapy
HK1183096B (en) Use of myeloid cell biomarkers for the diagnosis of cancer
HK1183096A (en) Use of myeloid cell biomarkers for the diagnosis of cancer
Paolini et al. Differential predictive value of resident memory CD8+ T cell subpopulations in non-small-cell lung cancer patients treated by immunotherapy
Sam CD27-CD70 interaction: novel predictive biomarker of immunotherapy in renal cell carcinoma and melanoma
Wang et al. Changes of immune function mediated by Gasdermin-E in the immune microenvironment of primary oral squamous cell carcinoma
Orozco-Levi et al. Lack of MICA expression predicts a worse prognosis in patients with bladder cancer
Kostine Defining the immune microenvironment in sarcoma: could immunotherapy be part of the treatment strategy in sarcoma patients?
Xu et al. Downregulation of HlxClosely Related to the Decreased Expressions of T-betand Runx3in Patients with Gastric Cancer May Be Associated with a Pathological Event Leading to the Imbalance of Th1/Th2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160803

Termination date: 20170921